Balyasny Asset Management
SEEL

Balyasny Asset Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Balyasny Asset Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,963
Closed -$224K – 3234
2024
Q1 		$224K Buy
2,963
+895
+43% +$118K ﹤0.01% 2363
2023
Q4 		$368K Buy
+2,068
New +$1.02M ﹤0.01% 2081
2022
Q3 		– Sell
-5
Closed -$13K – 3351
2022
Q2 		$13K Buy
+5
New +$13K ﹤0.01% 2547

Other funds holding SEEL

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CHA
Carmichael Hill & Associates Gaithersburg, Maryland $282M AUM 32.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's SEEL Position: Q2 2024 in Review

Balyasny Asset Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2024, closing a stake of 2,963 shares — an estimated $224K sold.

Balyasny Asset Management first reported a position in SEEL in Q2 2022 and held it in 3 quarters. The position peaked at $368K in Q4 2023. 18 funds tracked by Wall St. Rank hold SEEL as of Q2 2024.

  • Balyasny Asset Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 2,963 Seelos Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $224K.
  • Balyasny Asset Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Balyasny Asset Management's Seelos Therapeutics, Inc. Common Stock position peaked at $368K in Q4 2023.
  • 18 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.